logo
The Baseline
22 Sep 2026
Five stocks to buy from analysts this week - September 22, 2026
By Ruchir Sankhla

1. Avalon Technologies:

Motilal Oswal reiterates its ‘Buy’ rating on this electronics manufacturing services provider, with a target price of Rs 2,740, an upside of 11%. Analysts Sumant Kumar and Yash Darak believe the company will drive the next phase by expanding into high-value businesses like semiconductor equipment and battery energy storage systems (BESS). The company started commercial production of electronic power boxes in Q1FY27 for a top global semiconductor equipment maker after two years of development.

Management plans to build the semiconductor equipment business into a separate division over the next 18 to 24 months. To support this, they are building dedicated manufacturing facilities in Chennai. BESS is another major opportunity, especially in the US, where demand is rising because of investment in renewable energy, power grids and data centres. Avalon is also enhancing production for aerospace, railway safety systems, locomotive parts and satellite communication equipment.

Kumar and Darak predict these new businesses and faster order completion will accelerate Avalon's growth rate between FY27 and FY29. They forecast annual increases of 40% for revenue, 47% for EBITDA, and 56% for net profit. Semiconductor equipment and US energy storage demand will contribute heavily to this success, while higher-value products will boost profitability improvement.

2. Sagility:

Emkay initiates coverage on this healthcare services company with a ‘Buy’ rating and a target price of Rs 55, an upside of 20.6%. Analysts Dipeshkumar Mehta and Jimit Gandhi favour Sagility as they believe rising US healthcare spending and pressure on insurers to cut costs will push more companies to outsource their operations.

Sagility is perfectly positioned to capture this trend, drawing 90% of its revenue from US health insurers. It delivers essential, recurring services that support daily insurance operations. Analysts note that US national healthcare spending will rise 5.4% annually from 2026 to 2034, outpacing the broader economy, fueled by an ageing population, chronic diseases, and higher healthcare usage. They forecast Sagility’s revenue will improve 15% annually from FY27-29.

Management targets low double-digit revenue growth and a 24% to 25% EBITDA margin in FY27. The performance should come from deepening ties with existing clients, launching new services, and expanding among mid-sized US insurers. Mehta and Gandhi highlight that the company is also using acquisitions to add capabilities and clients. BroadPath brought around 30 client groups, while CareSeed added 26 and strengthened the company’s healthcare quality and analytics services.

3. Siemens Energy India (SEIL): 

Deven Choksey initiates coverage with a ‘Buy’ rating on this energy technology manufacturer, with a target price of Rs 4,554 per share, a 40.8% upside. Analyst Manik Jain calls the company a high-potential investment in India’s expanding power transmission and generation sectors. SEIL offers a broad portfolio covering grid infrastructure, power generation, engineering services, and research.

SEIL anticipates maintaining its dominance in the high-voltage direct current (HVDC) segment, where it holds a 30% market share. Expanding renewable energy networks, complex power grids, and the need for flexible power systems will drive a 16.5% annual revenue growth in the segment through FY30. SEIL also leads power generation, commanding a 55% market share in steam turbines. India's plans to build more thermal and nuclear power plants will create strong demand for these turbines over the long term.

Jain notes that SEIL is well-positioned to benefit from India’s transmission investment cycle through its diverse portfolio across transformers, switchgear, substations and grid-stabilisation solutions. SEIL is also increasing exports by using its Indian factories to supply global markets. Strong transformer capabilities and new US opportunities will boost export sales. He projects the firm to deliver annual growth rates of 25% for revenue and 35% for net profit between FY27 and FY29.

4. Federal Bank: 

Axis Direct retains its ‘Buy’ rating on this private bank with a higher target price of Rs 380, implying an upside of 16.2%. Analysts Dnyanada Vaidya and Abhishek Pandya remain positive on the bank, led by a strengthening deposit base and accelerating credit growth in focus segments like retail, commercial banking, and specialised assets.

Management estimates stronger growth in current accounts in FY27 as it expands its business banking operations and partnerships. The bank is also focusing on attracting more customers to its savings accounts by introducing premium offerings for high-income individuals, mass-affluent customers, and high net worth individuals. It doubled the pace of new current account openings last year and is encouraging employees to focus equally on bringing in deposits and giving out loans. A larger share of current and savings account deposits can help the bank keep its funding costs under control.

Federal Bank believes its loan book will climb at a mid-teens rate, supported by retail and business lending. Vaidya and Pandya highlight that an improved portfolio mix and stable deposit rates will boost asset yields. They believe the bank can scale up without taking excessive lending risks, helped by a well-diversified loan book and a wider customer base. Analysts expect income earned from lending to rise by around 19% annually and net profit by 26% annually through FY29.

5. Sakar Healthcare:

ICICI Direct maintains its ‘Buy’ rating on this small-cap pharma company, with a target price of Rs 1,310, an upside of 10.2%. Analysts Siddhant Khandekar and Shubh Mehta estimate that cancer medicines will generate up to Rs 100 crore in revenue in the long-term, driven by higher sales in Europe.

Sakar Healthcare is boosting production to meet rising demand for its cancer medicines. The company is also taking over the manufacturing of 10 cancer medicines from Accord-Intas, which sells these products in international markets. Eight of these have already received approval for sale, including five tablets and three injectable medicines.

Management anticipates securing 40 regulatory approvals to sell its medicines across overseas markets by the end of FY27 and up to 90 by FY28. These new approvals could add Rs 150-200 crore to annual revenue by FY29. The oncology business alone is expected to triple by FY28. Sakar is also growing its non-cancer business by manufacturing products for Zydus, Emcure, Glenmark, and Cipla, while increasing exports of blood-thinning medicines and antibiotics.

Khandekar and Mehta believe higher exports, new drug approvals, expanding production, and more in-house raw material manufacturing will boost revenue and margins. They add that Sakar recently cleared a European regulatory inspection and anticipates a positive final report.

 

Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

(You can find all analyst picks here)

More from The Baseline
More from Divyansh Pokharna
Recommended